Citations

Clear

126 citation(s) found for "Soliman, EZ".

Plasmacytoid dendritic cell-associated acute myeloid leukemia (pDC-AML) a comprehensive review
Abdalla, Azza, Al‐Mashdali, Abdulrahman , Hilmi, Feryal, Gangat, Naseema , Soliman, Dina A. , Fareed, Shehab, Al-Mashdali, Abdulrahman F , Ravandi, Farhad , Soliman, Dina

Mayo Clinic

Blood | December 5, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 6925-6925

10.1182/blood-2025-6925 Get It

Abstract Background: Plasmacytoid dendritic cell-associated acute myeloid leukemia (pDC-AML) is an emerging, rare subtype of AML characterized by the clonal proliferation of plasmacytoid dendritic cells (pDCs) at various stages of maturation. Although infrequent, this leukemia subtype is clinically aggressive and poses significant diagnostic and therapeutic challenges. Objective: This review synthesizes current knowledge on the immunophenotypic, genetic, and clinical features of pDC-AML, explores its prognostic implications, and compares it with the related entity blastic plasmacytoid dendritic cell neoplasm (BPDCN). Methods: A comprehensive literature search was conducted using databases including PubMed, Scopus, and Web of Science. Studies describing the morphology, immunophenotype, cytogenetics, molecular alterations, clinical presentation, and treatment outcomes of pDC-AML were included. Data were extracted and compiled from 16 studies encompassing 231 patients. Results: pDC-AML predominantly affects older adults (median age ~69 years) and exhibits a male predominance (~68%). It presents with diverse AML subtypes, including AML with monocytic differentiation, minimal differentiation, and secondary AML. Bone marrow pDCs range from 2.2% to 30% and exhibit variable maturation, often expressing CD123, CD303, CD304, and variably CD34 and CD117. In contrast to BPDCN, CD56 is rarely expressed, and skin or lymph node involvement is uncommon. Genetically, pDC-AML exhibits a complex landscape. RUNX1 mutations are the most common (14–78%), possibly driving pDC lineage commitment. Additional mutations include ASXL1, DNMT3A, SRSF2, FLT3, and BCOR. Chromosomal abnormalities such as chromosome 7 deletions, trisomy 13, and MLL or CBFA rearrangements are frequently observed. Compared to BPDCN—which shows high CD56 and TCL1 expression and more frequent TET2 mutations—pDC-AML is more genetically and phenotypically heterogeneous. Therapeutic responses are inconsistent. Treatments include induction chemotherapy, hypomethylating agents (e.g., azacytidine plus venetoclax), and allogeneic hematopoietic stem cell transplantation (allo-HSCT). Median overall survival ranges from 9.6 to 20 months, with frequent relapse even post-HSCT. Emerging therapies targeting CD123 (e.g., tagraxofusp) and immune-modulating agents are under investigation. Conclusion: pDC-AML is a clinically aggressive and biologically distinct AML subtype defined by clonal pDC expansion, frequent RUNX1 mutations, and suboptimal responses to current therapies. Accurate diagnosis relies on integrated immunophenotypic and genetic profiling. Despite progress, patient outcomes remain poor, underscoring the need for improved classification, prognostic markers, and targeted therapeutic strategies.
Contemporary adverse event profile of microsurgery for intracranial unruptured aneurysms in high-volume microsurgical centers: the international PRAEMIUM study
Adamides, Alexios A. , Başkaya, Mustafa K. , Ieva, Antonio Di , Lawton, Michael T., Pinna, Giampietro, Podlesek, Dino , Radovanovic, Ivan, Rohde, Veit, Stroh-Holly, Nico , Sturiale, Carmelo Lucio, _, _, Fierstra, Jorn , Laidlaw, John D., Evans, Lachlan R. , Sayyahmelli, Sara, Sayyahmelli, Sima , Štekláčová, Anna , Morgan, Michael K. , Acerbi, Francesco , Oushy, Soliman , Rinaldo, Lorenzo , Thomé, Claudius , Geiger, Philipp , Musumeci, Angelo , Schackert, Gabriele , Bervini, David , Raabe, Andreas, Mansur, Ann , Olijnyk, Leonardo, Malinova, Vesna , Mielke, Dorothée , Gmeiner, Matthias , Gruber, Andreas , Kondajji, and Aditya M., Oushy, Soliman H , Bervini, David , Staartjes, Victor E. , Anania, Pasquale , Beneš, Vladimír , Dehdashti, Amir R. , Ferroli, Paolo , Jakola, Asgeir Store , Lanzino, Giuseppe , Lawton, Michael T. , Petr, Ondra , Petutschnigg, Thomas , Rohde, Veit , Sturiale, Carmelo Lucio , Wang, Anthony , Regli, Luca , Esposito, Giuseppe, _, _, Serra, Carlo , Sebök, Martina , Germans, Menno Robbert , Zona, Gianluigi , Fiaschi, Pietro , Yang, Kaiyun , Acerbi, Francesco , Vetrano, Ignazio G. , Klurfan, Paula , Catapano, Joshua S , Meneghelli, Pietro , Goldberg, Johannes , Gruber, Andreas, Auricchio, Annamaria , Olivi, Alessandro , Colby, Geoffrey P.

Mayo Clinic

Neurosurgical Focus | December 1, 2025 | Volume: 59 | Issue: 6 | Pages: E18

10.3171/2025.9.focus25723 | PMID 41343785 Get It

OBJECTIVE Objective values on procedural risk are essential to facilitate informed consent and optimize clinical decision-making in patients with unruptured intracranial aneurysms (UIAs). While robust heuristics, such as the PHASES (population, hypertension, age, size of aneurysm, earlier subarachnoid hemorrhage, and site of aneurysm) score, are established for predicting rupture risk, contemporary and granular benchmarks for procedural safety remain scarce. The multinational Prediction of Adverse Events After Microsurgery for Intracranial Unruptured Aneurysms (PRAEMIUM) study aims to comprehensively characterize contemporary adverse event rates following microsurgical treatment at high-volume expert centers, stratified by aneurysm location, morphology, and complexity factors to better inform individual risk/benefit analyses. METHODS A cohort study among 20 participating expert centers from 9 countries was established. Patients treated microsurgically for UIAs were included. The authors describe the epidemiology of treated patients and UIAs and a comprehensive adverse event profile using 3 outcomes measured at hospital discharge: 1) poor neurological outcome (modified Rankin Scale score ≥ 3), 2) new sensorimotor neurological deficits, and 3) all-cause adverse events (Clavien-Dindo grade ≥ 1). Subgroup reports were given for aneurysm location, morphology, and complexity factors (prior aneurysm treatment, calcifications, complex angioanatomy involving critical branch vessels or perforators, and thrombosis). The authors purposely chose discharge as the time point to capture early postoperative risks and complications in patients with asymptomatic UIAs, for whom preserving neurological function is paramount. RESULTS The cohort included 3705 patients (mean age 56 [SD 12] years, 28% male). Overall, at discharge 13.9% of patients (95% CI 12.8%–15.0%) had poor neurological functional outcomes, 14.4% (95% CI 13.3%–15.5%) had new sensorimotor deficits, and 24.1% (95% CI 22.8%–25.5%) experienced all-cause adverse events. Poor neurological outcomes ranged from 8.5% (M1 aneurysms) to 37.4% (posterior circulation aneurysms), neurological deficits from 9.3% (distal anterior cerebral artery [ACA] aneurysms) to 34.2% (posterior circulation aneurysms), and all-cause adverse events from 21.2% (distal ACA aneurysms) to 31.3% (posterior circulation aneurysms). Dissecting and fusiform aneurysms showed notably high rates of poor neurological outcomes (22.0%–33.3%), new deficits (25.4%–26.7%), and adverse events (26.7%–37.0%). Complexity factors significantly influenced outcomes, with prior treatment (22.9%, 19.7%, and 30.1%), calcification (16.3%, 18.1%, and 30.5%), complex angioanatomy (13.1%, 15.9%, and 26.9%), and thrombosis (19.6%, 23.9%, and 39.6%) notably increasing the risks for poor neurological outcomes, deficits, and adverse events, respectively. CONCLUSIONS This large international cohort provides contemporary benchmarks for microsurgical treatment of UIAs, emphasizing variability in outcomes based on aneurysm location, morphology, and complexity. The presented granular and quotable adverse event rates support informed patient counseling and individualized risk/benefit assessments in comparable high-volume centers.
NCCN Guidelines® Insights: Breast Cancer, Version 5.2025
Gradishar, William J. , Moran, Meena S. , Abraham, Jame , Aft, Rebecca , Allison, Kimberly H. , Anderson, Bethany , Bailey, Janet E., Burstein, Harold J. , Chen, Nan , Chew, Helen K. , Dang, Chau T. , Jankowitz, Rachel C. , Javid, Sara H. , Leitch, A. Marilyn , Lyons, Janice A., McCloskey, Susie, McShane, Melissa , Patel, Sameer A. , Santa‐Maria, Cesar A. , Schneider, Bryan P. , Smith, Mary Lou , Stringer-Reasor, Erica , Telli, Melinda L. , Wei, Mei , Wisinski, Kari B. , Yellala, Amulya, Schonfeld, Ryan, Kumar, Rashmi , Telli, Melinda L , Abramson, Vandana G. , Agnese, Doreen Marie , Elias, Anthony , Giordano, Sharon H. , Goetz, Matthew P. , Krishnamurthy, Jairam , Mortimer, Joanne , Rosenberger, Laura H. , Rugo, Hope S. , Santa-Maria, Cesar Augusto , Soliman, Hatem Hussein , Yeung, Kay T. , Young, Jessica S.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | November 10, 2025 | Volume: 23 | Issue: 11 | Pages: 426-436

10.6004/jnccn.2025.0053 | PMID 41213254 Get It

The treatment landscape of invasive early-stage and metastatic breast cancer is evolving constantly. These NCCN Guidelines Insights focus on recent updates included in the most recent version (version 5.2025) of the NCCN Guidelines for Breast Cancer specific to workup, locoregional therapy, surveillance, and systemic neoadjuvant/adjuvant therapy recommendations for invasive, nonmetastatic breast cancer.
Abstract 4368666: Prognosis of right bundle branch block in heart failure patients: a reconstructed time-to-event meta-analysis
Almaadawy, Omar , Mostafa, Naydeen , Hamed, Belal, Abdelsattar, Nada K. , Sarhan, Menna , Soliman, Esraa , Mohyeldin, Eman, Zreigh, Sofian , Rustm, Mohamad, HASSAN, ABDULAHI, Elbenawi, Hossam , Georges, Claudia, Ahmed, Mustafa M. , Mansour, Ahmed , Hamed, Belal, Taha, Taha E. , Rustm, Mohamad , HASSAN, ABDULAHI, Mansour, Ahmed

Mayo Clinic

Circulation | November 3, 2025 | Volume: 152 | Issue: Suppl_3 | Pages: No page available

10.1161/circ.152.suppl_3.4368666 Get It

Background: The growing epidemiologic burden of heart failure (HF) poses a significant public health challenge. The development of conduction abnormalities influences HF outcomes, with left bundle branch block (LBBB) established as an independent mortality predictor. However, the impact of right bundle branch block (RBBB) on HF mortality is still controversial. The aim of this study is to compare survival in HF patients with and without RBBB. Methods: A comprehensive search was conducted on PubMed, Scopus, Web of Science, and Cochrane Library from inception to 12 October 2024. Raw data coordinates were extracted from Kaplan–Meier curves and merged into one dataset to reconstruct individual patient data. Hazard ratios (HR) with 95% confidence intervals (CI) were estimated using the Cox regression model. Dichotomous outcomes were pooled as risk ratios (RR) with 95% confidence interval (CI) using a random-effects model. Results: 13 studies incorporating 25714 HF patients were included in our analysis. Patients with RBBB had a significantly lower median survival of 41.0 months (95% CI: 39.0 – 44.8) compared to 51.2 months (95% CI: 49.2 – 52.8) in patients without RBBB. Survival at 1,3, and 5 years in RBBB patients was 74.2%, 54.0%, and 39.4%, respectively, compared to 77.2%, 58.1%, and 45.4% in patients without RBBB. The HR for mortality was 0.87 (95% CI: 0.83 – 0.91, p < 0.001), indicating a 13% lower risk of death in patients without RBBB compared to those with RBBB. There was no significant difference in cardiovascular mortality between groups (RR: 1.34; 95% CI: 0.88 – 2.05; p = 0.17). Conclusion: RBBB was associated with an increased risk of mortality in HF patients. These findings support the use of RBBB as a potential marker for risk stratification in HF. Further research with stricter inclusion criteria is warranted to better understand how the observed association is influenced by preserved versus reduced ejection fraction.
Predictors and Prognosis of Right Bundle Branch Block Following Heart Transplantation: A Systematic Review and Meta‐Analysis
Mostafa, Naydeen , Almaadawy, Omar , Dervis, Muhiddin , Asad, Amar, Zreigh, Sofian , Soliman, Esraa , Mostafa, Hamed Abdelma’aboud , Elbenawi, Hossam , Ahmed, Mustafa M. , Ahmed, Mustafa , Elshahat, Ahmed , Hamed, Belal Mohamed , Asad, Amar

Mayo Clinic

Clinical Transplantation | September 16, 2025 | Volume: 39 | Issue: 9 | Pages: No page available

10.1111/ctr.70322 | PMID 40956277 Get It

ABSTRACT Background Right bundle branch block (RBBB) has a high prevalence among heart transplant recipients and could influence outcomes. Crucially, the predictors of RBBB development after heart transplantation are not well‐established. Our study aims to evaluate the preoperative predictors and outcomes of RBBB following heart transplantation. Methods PubMed, Scopus, Web of Science, and Cochrane Library were searched up to November 15, 2024, to identify studies comparing heart transplant recipients with RBBB and without RBBB. Random‐effects models were used to estimate the pooled mean difference (MD) and risk ratios (RRs) with 95% confidence intervals (95% CIs). Results Nine studies incorporating 1507 patients were included. Patients who developed RBBB had higher graft ischemia time [MD: 10.0; 95% CI: 2.00–17.91; p = 0.01] and pulmonary vascular resistance (PVR) (MD: 0.44; 95% CI: 0.21–0.68; p < 0.001). There was no significant difference between RBBB and non‐RBBB patients in terms of pulmonary artery pressure (MD: 1.83; 95% CI: ‐0.86–4.53; p = 0.18) or donor age (MD: 1.51; 95% CI: ‐0.30– 3.31; p = 0.10). There was no significant difference in the prognosis of RBBB patients in terms of acute rejection (RR: 1.06; 95% CI: 0.70–1.61; p = 0.78), chronic rejection (RR: 0.92; 95% CI: 0.60–1.41; p = 0.70), or mortality (RR: 1.87; 95% CI: 0.81–4.31; p = 0.14). Conclusion Despite the association of RBBB with graft ischemia time and PVR, post‐transplant RBBB had no significant impact on mortality or graft rejection. Further research focusing on the identification period and applied definition of RBBB is recommended.
American Board of Internal Medicine’s Pilot Pathway to Board Eligibility for International Medical Graduates
Daoud, Ahmed , Kamal, Ahmed , Barakat, Munsef, Naeem, Ubaid, Bakhaty, Omar, Herberth, Johann , Cheungpasitporn, Wisit , Campbell, Ruth , Fülöp, Tibor , Soliman, Karim , Cheungpasitporn, Wisit , Fülöp, Tibor , Soliman, Karim M , Naeem, Ubaid

Mayo Clinic

Clinical Journal of the American Society of Nephrology | September 5, 2025 | Volume: 20 | Issue: 12 | Pages: 1814-1817

10.2215/cjn.0000000823 | PMID 40911355 Get It

NCCN Guidelines® Insights: Uterine Neoplasms, Version 3.2025
Abu‐Rustum, Nadeem R. , Campos, Susana M. , Amarnath, Sudha, Barber, Emma L. , Bradley, Kristin , Brooks, Rebecca , Chino, Junzo , Chon, Hye Sook, Damast, Shari , Fisher, Christine M. , Frederick, Peter J., Gaffney, David K. , Giuntoli, Robert , Glaser, Scott , Howitt, Brooke E. , Landrum, Lisa M. , Mantia-Smaldone, Gina , Mariani, Andrea , Nagel, Christa , Nieto, Karina , Nwachukwu, Chika , Podoll, Mirna, Rodabaugh, Kerry J. , Salani, Ritu , Schorge, John O., Schuetze, Scott M. , Siedel, Jean , Sisodia, Rachel, Soliman, Pamela T. , Ueda, Stefanie , Urban, Renata R. , Wyse, Emily , McMillian, Nicole R., Arend, Rebecca C. , Crispens, Marta Ann , Gaillard, Stéphanie , Lea, Jayanthi Sivasothy , Lee, Nita Karnik , Mutch, David G. , Nekhlyudov, Larissa , Sambandam, Vaishnavi

Mayo Clinic

Journal of the National Comprehensive Cancer Network | August 5, 2025 | Volume: 23 | Issue: 8 | Pages: 284-291

10.6004/jnccn.2025.0038 | PMID 40763788 Get It

The NCCN Guidelines for Uterine Neoplasms provide recommendations for diagnostic workup, clinical staging, and treatment options for patients with endometrial cancer and uterine sarcoma. The NCCN Cervical Uterine Panel meets at least annually to review comments from reviewers within their institutions; examine relevant new data from publications, abstracts, and recent FDA approvals; and reevaluate and update recommendations. These NCCN Guidelines Insights summarize the panel’s deliberations on the new FIGO 2023 staging system and updates on the new systemic therapy recommendations for the management of endometrial cancer.
A practical guide for nephrologist peer reviewers: evaluating artificial intelligence and machine learning research in nephrology
Wang, Yanni , Cheungpasitporn, Wisit, Qing, Jianbo , Kaewput, Wisit , Soliman, Karim , Cheungpasitporn, Wisit , Kaewput, Wisit , Soliman, Karim M , Zhang, Zhongheng , Cheungpasitporn, Wisit , Ali, Hatem , Thongprayoon, Charat , Huang, Zhengxing , Yang, Min

Mayo Clinic

Renal Failure | July 7, 2025 | Volume: 47 | Issue: 1 | Pages: No page available

10.1080/0886022x.2025.2513002 | PMID 40620096 Get It

Immune Subtyping Identifies Patients With Hormone Receptor–Positive Early-Stage Breast Cancer Who Respond to Neoadjuvant Immunotherapy (IO): Results From Five IO Arms of the I-SPY2 Trial
Wolf, Denise M. , Yau, Christina , Glas, Annuska M. , Barcaru, Andrei, Kuilman, Midas M. , Swigart, Lamorna Brown , Hirst, Gillian L. , Basu, A. , Magbanua, Mark Jesus M. , Sayaman, Rosalyn W. , Huppert, Laura A. , Investigators, I-SPY2, Borowsky, Alexander D. , Pohlmann, Paula R. , Clark, Amy S. , Yee, Douglas , Perlmutter, Jane , Petricoin, Emanuel F. , Chien, A. Jo , Stringer-Reasor, Erica , Liu, Minetta C. , Nanda, Rita , Veer, Laura van ‘t , Melisko, Michelle , Albain, Kathy S. , Robinson, Patricia A. , Lo, Simon S. , Potter, David J. , Beckwith, Heather , Haddad, Tufia C. , Kemmer, Kathleen, Lu, Janice , Williams, Nicole , Ellis, Erin D. , Sanford, Amy, Sanft, Tara, Viscusi, Rebecca K., Arora, Mili, Northfelt, Donald W. , Haley, Barbara , Yung, Rachel L. , Mayer, Ingrid, Khan, Qamar J. , Edmiston, Kirsten K., Glas, Annuska , Mittempergher, Lorenza , Brown-Swigart, Lamorna , Hirst, Gillian L , Basu, Amrita , Magbanua, Mark J M , Sayaman, Rosalyn , Huppert, Laura , Delson, Amy , Symmans, W Fraser , Pohlmann, Paula , Rugo, Hope S , Clark, Amy S , Yee, Douglas , DeMichele, Angela , Petricoin, Emmanuel F , Chien, Jo , Stringer-Reasor, Erica , Shatsky, Rebecca , Liu, Minetta , Soliman, Hatem Hussein , Isaacs, Claudine , Nanda, Rita , Hylton, Nola M. , Pusztai, Lajos , Esserman, Laura J , Veer, Laura J. van’t , Campbell, Michael, Investigators, I-SPY2, Symmans, W. Fraser , Rugo, Hope S. , DeMichele, Angela , Shatsky, Rebecca , Han, Hyo S , Isaacs, Claudine , Pusztai, Lajos , Esserman, Laura J. , Mukhtar, Rita A. , Wallace, Anne M. , Yeung, Kay T. , Olopade, Olufunmilayo I. , Potter, David, Blaes, Anne , Boughey, Judy C. , Elias, Anthony , Mitri, Zahi Ibrahim , Lang, Julie E. , Thomas, Alexandra , Trivedi, Meghna S. , Hershman, Dawn L. , Meisel, Jane Lowe , Kalinsky, Kevin M. , Vaklavas, Christos , Sanft, Tara , Arora, Mili, Falkson, Carla I. , Murthy, Rashmi Krishna

Mayo Clinic

JCO Precision Oncology | June 17, 2025 | Volume: No volume available | Issue: 9 | Pages: No page available

10.1200/po-24-00776 | PMID 40526879 Get It

PURPOSE Neoadjuvant immunotherapy (IO) has become the standard of care for early-stage triple-negative breast cancer (TNBC), but not yet for other subtypes. We previously developed a clinical-grade mRNA-based immune classifier (ImPrint) predicting response to IO that is now being used in I-SPY2.2 as part of the response predictive subtypes. We report the performance of ImPrint in hormone receptor–positive and human epidermal growth factor receptor 2–negative (HR+HER2–) patients from five IO arms. METHODS A total of 204 HR+HER2– (MammaPrint high-risk) patients from five IO arms (anti–PD-1, anti–PD-L1/poly [ADP-ribose] polymerase inhibitor combination, anti–PD-1/toll-like receptor 9 dual-IO combination, and anti–PD-1 ± lymphocyte activation gene 3 dual-IO combination) and 191 patients from the chemotherapy-only control arm were included in this analysis. Patients were classified as ImPrint+ (likely sensitive) versus ImPrint– (likely resistant), using pretreatment mRNA. Performance of ImPrint for predicting pathologic complete response (pCR) to IO-containing arms was characterized and compared with tumor grade (III), MammaPrint (ultra) High2 risk (MP2), and estrogen receptor (ER)-low (ER ≤ 10%). RESULTS Overall, the pCR rate across the five IO arms was 33%. 26% of HR+HER2– patients were ImPrint+, and pCR rates with IO were 75% in ImPrint+ versus 17% in ImPrint–, with the highest pCR rate >90% in a dual-IO arm. In the control arm, pCR rates were 33% in ImPrint+ and 8% in ImPrint–. Tumor grade (III), MP2, and ER-low showed pCR rates in IO of 45%, 56%, and 63%, respectively, with lower pCR odds ratios (OR < 7.5) compared with ImPrint (OR = 14.5). CONCLUSION Using an accurate selection strategy, HR+HER2– patients could achieve pCR rates similar to what is seen with best neoadjuvant therapies in TNBC and HER2+ (ie, pCR rate >65%-70%). ImPrint, an Food and Drug Administration IDE-enabled assay, may represent a way to identify HR+HER2– patients for IO that best balances likely benefit versus risk of serious immune-related adverse events.